12/22/2021
With a grant from the American Cancer Society, Dr. Karaayvaz’s team will investigate the molecular connections linking BRCA2 to breast cancer development with the goal of developing innovative strategies for breast cancer risk assessment and prevention.
Mihriban Karaayvaz, PhD, assistant staff in the Genomic Medicine Institute, has been awarded a one-year, $40,000 grant from the American Cancer Society to investigate the molecular details of the early changes in human breast cells observed in BRCA2-associated breast cancer.
Women with germline (heritable changes affecting all cells in the body) mutations of BRCA2 have an elevated risk of developing breast cancer compared to the general population. While a prophylactic double mastectomy (surgical removal of both breasts) presents as an effective preventive strategy, many women remain reluctant to undergo the surgical procedure. Therefore, there is an urgent clinical need for additional, nonsurgical alternatives for breast cancer prevention in patients with BRCA2 mutations.
With this new grant, Dr. Karaayvaz’s team will unravel the molecular circuitry linking BRCA2 function, replication stress response and cellular transformation in human breast cells. Their findings should help pave the way for the development of innovative strategies for breast cancer risk assessment and prevention.
Assistant Staff
Lab Profile
Dr. Eng and colleagues found that the breast microbiome may modulate local immune responses that lead to breast cancer.
Led by Drs. Keri and Eng, the center will support a multi-investigator research team focused on discerning the role of the tumor microenvironment in breast cancer progression.
Breast cancer often relies on characteristics of healthy breast cell development, and the developmental regulator TLE3 could play a role in suppressing the spread of breast tumors.
The future of health starts with your support. Donations supply researchers with the tools, space and staff they need to think big.
Give to Cleveland Clinic